Advertisement

Infection

, Volume 19, Supplement 6, pp S320–S325 | Cite as

Nosocomial pneumonia: Comparative multicentre trial between monotherapy with cefotaxime and treatment with antibiotic combinations

  • M. Fernández-Guerrero
  • C. Arnau
  • L. Valdés
  • C. Vallvé
  • F. Gudiol
  • A. Rodríguez-Torres
Article

Summary

In a multicentre clinical trial involving 32 hospitals, 588 adult patients diagnosed with nosocomial pneumonia and not receiving mechanical ventilation were treated randomly with monotherapy with cefotaxime or the antibiotic combination routinely used in each particular hospital. Both groups of patients were similar regarding demographic data, concurrent diseases, additional therapies and causative organism. Protocol violations were recorded in 40 patients, and these patients were excluded from the evaluation of treatment efficacy. The cure rate was 79% in the cefotaxime group and 71% in the group receiving antibiotic combinations; this difference is statistically significant (p=0.03, Fisher's two-tailed test). In the patients receiving combinations of cephalosporins having activity predominantly against gram-positive organisms plus aminoglycosides, the cure rate obtained was very low. The frequency of serious adverse reactions was significantly higher in the group treated with antibiotic combinations. It is concluded that montherapy with cefotaxime is the regimen that offers better results for the empirical treatment of nosocomial pneumonia.

Keywords

Cephalosporin Cefotaxime Aminoglycosides Nosocomial Pneumonia Multicentre Clinical Trial 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Behandlung der nosokomialen Pneumonie mit Cefotaxim allein oder einer Antibiotikakombination. Multizentrische Vergleichsstudie

Zusammenfassung

In einer multizentrischen Studie wurden 588 Erwachsene mit nosokomialer Pneumonie, die nicht beatmungspflichtig waren, in 32 Krankenhäusern randomisiert entweder mit Cefotaxim allein oder der jeweils üblichen Kombinationstherapie behandelt. Nach demographischen Daten, Begleitkrankheit, Zusatztherapien und kausalem Erreger waren die beiden Gruppen vergleichbar. 40 der Patienten wurden wegen Protokollverletzung von der Auswertung bezüglich therapeutischer Wirksamkeit ausgeschlossen. Die Heilungsrate betrug in der Cefotaxim-Gruppe 79%, in der Vergleichsgruppe 71%. Dieser Unterschied ist statistisch signifikant (p=0,03, Fisher's two-tailed test). Bei Patienten, die mit einer Kombination aus einem vorwiegend gegen grampositive Erreger wirksamen Cephalosporin mit einem Aminoglykosid behandelt wurden, war die Heilungsrate sehr gering. Bei Behandlung mit den Antibiotikakombinationen traten signifikant mehr ernste Nebenwirkungen auf. Für die empirische Therapie der nosokomialen Pneumonie bietet die Behandlung mit Cefotaxim folglich bessere Möglichkeiten.

References

  1. 1.
    Centers for Disease Control National Nosocomial Infections Study Report. Annual Summary 1984. MMWR 35 (1986) 17ss-29ss.Google Scholar
  2. 2.
    Garibaldi, R. A., Britt, M. R., Coleman, M. L., Reading, J. C., Pace, N. L. Risk factors for postoperative pneumonia. Am. J. Med. 70 (1981) 677–680.Google Scholar
  3. 3.
    Gross, P. A., Neu, H. C., Aswaspokee, P., Van Antwerpen, C., Aswapokee, N. Deaths from nosocomial infections: experience in a university hospital and a community hospital. Am. J. Med. 68 (1980) 219–223.Google Scholar
  4. 4.
    Wimberley, N., Faling, L. J., Bartlett, J. G. A fiberoptic bronchoscopy technique to obtain uncontaminated lower airway secretions for bacterial culture. Am. Rev. Respir. Dis. 119 (1979) 337–343.Google Scholar
  5. 5.
    Chastre, J., Viau, F., Brun, P., Pierre, J., Dauge, M. C., Bouchana, A., Akesbi, A., Gibert, C. Prospective evaluation of the protected specimen brush for the diagnosis of pulmonary infections in ventilated patients. Am. Rev. Respir. Dis. 130 (1984) 924–929.Google Scholar
  6. 6.
    Pennington, J. E. Nosocomial respiratory infection. In:Mandell, G. L., Douglas, R. G., Bennett, J. E. (eds.): Principles and practice of infectious disease. Third edition. Churchill Livingstone, New York (1990) pp. 2199–2205.Google Scholar
  7. 7.
    Organización Mundial de la Salud: Clasificación Internacional de Enfermedades. Washington 1978.Google Scholar
  8. 8.
    Catálogo de especialidades farmacéuticas. Departamento Técnico. Consejo General de Colegios Oficiales de Farmacéuticos. Madrid 1989.Google Scholar
  9. 9.
    Eliopoulos, G. M., Eliopoulos, C. T. Antibiotic combinations: should they be tested? Clin. Microbiol. Rev. 1 (1988) 139–156.Google Scholar
  10. 10.
    Todd, P. A., Brogden, R. N. Cefotaxime. An update of its pharmacology and therapeutic use. Drugs 40 (1990) 608–651.Google Scholar
  11. 11.
    Cone, L. A., Woodard, D. R., Stolzman, D. S., Byrd, R. G. Ceftazidime versus tobramycin-ticarcillin in the treatment of pneumonia and bacteremia. Antimicrob. Agents Chemother. 28 (1985) 33–36.Google Scholar
  12. 12.
    Greenberg, R. N., Reilly, P. M., Luppen, K. L., Bollinger, M., Mc Millan, R. Aztreonam therapy for gram-negative pneumonia. Am. J. Med. 78s (1985) 31–33.Google Scholar
  13. 13.
    Salata, R. A., Gebhart, R. L., Palmer, D. L., Wade, B. H., Scheld, W. M., Groschel, D. H. M., Wenzel, R. P., Mandell, G. L., Duma, R. J. Pneumonia treated with imipenem/cilastin. Am. J. Med. 78s (1985) 104–109.Google Scholar
  14. 14.
    Carmine, A. A., Brogden, R. N., Heel, R. C., Speight, T. M., Avery, G. S. Cefotaxime: a review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs 25 (1983) 223–289.Google Scholar
  15. 15.
    Reeves, J. H., Russell, G. M., Cade, J. F., McDonald, M. Comparison of ceftriaxone with cefotaxime in serious chest infections. Chest 96 (1989) 1292–1297.Google Scholar
  16. 16.
    Pallarés, R., Gudiol, F., Liñares, J., Viladrich, P. Bacteremic pneumonia caused by penicillin-resistant pneumococci. N. Engl. J. Med. 318 (1988) 124–128.Google Scholar
  17. 17.
    Moore, R. D., Smith, C. R., Lietman, P. S. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am. J. Med. 77 (1984) 657–662.Google Scholar

Copyright information

© MMV Medizin Verlag GmbH München 1991

Authors and Affiliations

  • M. Fernández-Guerrero
    • 1
  • C. Arnau
    • 1
  • L. Valdés
    • 1
  • C. Vallvé
    • 1
  • F. Gudiol
    • 2
  • A. Rodríguez-Torres
    • 3
  1. 1.Division of Infectious DiseaseFundación Jiménez DíazMadridSpain
  2. 2.Infectious Disease ServiceHospital Príncipes de EspañaBarcelonaSpain
  3. 3.Department of Clinical MicrobiologyHospital ClínicoValladolidSpain

Personalised recommendations